Another five drugs were effective against some but not all of the Mz-resistant parasites. This study provides the incentive for the continued design of 5-nitroimidazole drugs to bypass cross-resistance among established 5-nitromidazole antiparasitic drugs.
Metronidazole (Mz) and a related 5-nitroimidazole, tinidazole, are the only drugs recommended for the treatment of trichomoniasis and are the most-prescribed drugs for the treatment of giardiasis. However, clinical resistance to these drugs has been well documented; and in the event of overt clinical resistance to Mz in trichomonads, there is no alternative for treatment, when one keeps in mind the documented crossresistance between the currently used 5-nitroimidazole drugs and their worldwide availability (7, 8, 18, 23) . Some success has been obtained with quinacrine and albendazole in combination with Mz in cases of giardiasis treatment failures (23) . On the positive side, a great deal of flexibility is offered by the side chains attached to the imidazole ring structure that bear the all important nitro group (17) .
The mechanisms of Mz resistance in Giardia and Trichomonas have been well studied in laboratory-induced resistance (18) . It occurs by down-regulation of pathways, especially the enzyme pyruvate:ferredoxin oxidoreductase (PFOR) and ferredoxin (Fd) pathway, that activate Mz to its toxic radical state. The PFOR-Fd couple has an electron potential sufficiently low to activate Mz, while no such electron couple is present in the mammalian host (9) . In the laboratory we see a threefold down-regulation of PFOR activity in Mz-resistant (Mz r ) Giardia duodenalis (14) , and in highly Mz r Trichomonas vaginalis the activity of the hydrogenosome organelle is downregulated such that there is no detectable PFOR or Fd expression (4, 11, 18) . Thus, Mz is not activated to its toxic radical state in these cells. On the other hand, it is well documented that clinically Mz r T. vaginalis strains do not have down-regulated hydrogenosomes, and the mechanism of Mz resistance in these cells is not understood (8) .
Previously, we showed that some 5-nitroimidazole derivatives were significantly more effective antiprotozoal agents (based on in vitro molar drug concentrations) than Mz against Parasites were cultured axenically in anaerobic TYI-S-33 (6), which was modified as described previously (16 All new 5-nitroimidazole compounds ( Fig. 1 ) were identified by spectral data, purified by chromatography on silica gel columns, and recrystallized from appropriate solvents. Their purities were checked with appropriate controls by thin-layer chromatography and elemental analysis (C, H, N). The purity was always over 99.6%. The synthesis of compounds 1 to 9, 10 to 16, 17 to 19, 20 to 23, and 24 to 28 were as described in references 2, 1, 20, 21, and 22, respectively. The reaction of compound 28 with 2-nitropropane or nitrocyclohexane anion led to the C-alkylation products 29 and 30, respectively, by the S RN Table  1 ). The significance of the data presented in Table 1 is the low in vitro MICs for six 5-nitroimidazole compounds against some or all of the Mz r parasites tested. No other 5-nitroimidazole compounds tested so far were inhibitory to the Mz r parasites used in this study.
The most effective drug overall, compound 14, differs in structure from compound 16 ( Fig. 1) by the remote substituents of the side chain attached at the 2 position on the nitroimidazole ring, notably, a nitro group in compound 14 but not in compound 16, which showed no inhibition of two Mz s G. duodenalis isolates (MICs ϭ 100 M). Other compounds with remote nitro groups (compounds 20, 21, 22, 23, 29, and 30; Fig.  1 ) did not inhibit Mz r parasites (MICs Ն 100 M). We also tested a number of quinoxaline and 3,4-diphenylfuran derivatives with and without nitro groups (unpublished synthesis data) and p-nitrobenzyl derivatives (3), none of which were effective antiprotozoal agents (data not shown). 1.6, 3.1, 6 .3, and 6.3 M, respectively. The most highly Mz r isolate was DUR36 (Table 1) . Compounds 14, 17, and 18 therefore provide precedence for the design of new 5-nitroimidazole antitrichomonal drugs. It has been claimed that the eradication of trichomoniasis may well be the single most cost-effective step in human immunodeficiency virus infection incidence reduction (5, 10, 12) , and for this reason the development of drugs for the treatment of cases of Mz rc T. vaginalis has been a focus of our work (8, 16) .
Previously, we reported that among a 5-nitroimidazole series of compounds, the most antimicrobial and antiparasitic compounds showed a greater resonance conjugation in the molecular structure (17, 19) . For this study, we have synthesized under mild conditions and in good yields highly conjugated 5-nitroimidazole derivatives using electron transfer reactions (S RN 1, LD-S RN 1, bis-S RN 1, and E RC 1 [1, 2, 20, 21, 22] ). By increasing the conjugated system, we have developed some highly active compounds, especially the C-alkylation products obtained by LD-S RN 1, compounds 8 and 14. The present study again demonstrates the importance of the 5-nitroimidazole side chain in antiparasitic activity (e.g., compounds 3 and 7 are E and Z isomers, and the differences between the antiprotozoal activities of compounds 14 and 16 and between compounds 18 and 19). These dramatic differences may relate to solubility and membrane permeability. The positive influence of bromine (compound 17), a sulfonyl group (compounds 3 and 7), or a dioxole nucleus (compound 18) were noted, but deprotection of the remote dioxole ring in compound 18 resulted in the formation of the diphenol compound 19, which was detrimental to protozoocidal activity.
These data suggest that the 5-nitro group is highly active in compound 14, but it does not explain why this drug is so active against Mz rl T. vaginalis, which supposedly does not have the ability to reduce Mz (4). We have previously identified alternative 2 oxoacid oxidoreductase (OR) activity in Mz rl T. vaginalis (4), and it is possible that these alternative ORs are responsible for the activation of compound 14 to its toxic radical state.
There are examples in the literature of patients who have failed to respond to all antigiardial or antitrichomonal treatments (7, 23) . Here we have shown that at least three different 5-nitroimidazole compounds, including one that is readily synthesized, inhibited highly Mz rl G. duodenalis and Mz rc T. vaginalis isolates. The clinical application of such drugs may well overcome the documented cross-resistance among the 5-nitroimidazole drugs, and the lead compounds described here provide the basis from which new 5-nitroimidazole drugs clinically active against Mz r Trichomonas and Giardia can be derived. 
